Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | HARS1 | P12081 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137858 | 0.85 | CYP3A4 (0.42) | CYP3A4SLC7A5HARS1HRH3NLN | |
| SCHEMBL23104578 | 0.81 | AMDHD2 (0.35) | — | |
| SCHEMBL6436202 | 0.69 | CYP3A4 (0.61) | CYP3A4SLC7A5HRH3 | |
| SCHEMBL3393715 | 0.69 | CYP3A4 (0.65) | CYP3A4SLC7A5HRH3 | |
| SCHEMBL93943 | 0.69 | CYP3A4 (0.65) | CYP3A4SLC7A5HRH3 | |
| SCHEMBL1000946 | 0.69 | CDK1 (0.51) | CYP3A4SLC7A5HARS1 | |
| Hydrochloric Acid SCHEMBL28535120 | 0.68 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH3 | |
| Hydrochloric Acid SCHEMBL5491525 | 0.68 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH3 | |
| Hydrochloric Acid SCHEMBL3393714 | 0.68 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH3 | |
| SCHEMBL3846866 | 0.68 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, GLA | CYP3A4 3581/4885SLC7A5 454/4885HARS1 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.